Guardian Bio is a therapeutics platform creating the next generation of cell-based cancer vaccines for late stage, solid tumor cancer patients. The proprietary platform is based on conventional dendritic cells type 1 (cDC1s), recently defined and identified as primary drivers of anti-cancer immunity. Guardian Bio differentiates a patient’s stem cells into a cDC1-based therapy that drives robust immune responses against multiple cancer targets. Our goal is to bring cancer vaccines and immunotherapy to a new world of patients. The Guardian Bio platform has already demonstrated the ability to selectively and robustly activate killer T cell populations against multiple cancer targets simultaneously, including from late stage cancer patient material. This results in specific killing of target cells with little off target killing, representing both efficacy and safety.